Ovid Therapeutics, Inc. logo

Ovid Therapeutics, Inc.

Ovid Therapeutics is a biopharmaceutical firm focused on developing therapies for rare and orphan diseases of the brain. Ovid Therapeutics is a biopharma company, focus on discovery and development of therapies for rare and orphan diseases of the brain.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”OVID” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.ovidrx.com
Founded2014
Disease Focus
Development Stage
STOCK CODENASDAQ: OVID
Address
1460 Broadway, NY 10036
New York
United States
Email
Contact Number
+1 646-661-7661

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/ovid-therapeutics” connections=”true” suffix=””]

In July 2018, Ovid and Takeda Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE). The Three Planned Clinical Studies Are Phase 2 ARCADE Trial, Phase 2 ELEKTRA Trial and ENDYMION. Under the terms of the agreement, the companies share in the development and commercialization costs and profits on a 50/50 basis. Takeda will lead commercialization in Japan, and has Asia and other selected geographies. Ovid leads clinical development activities and commercialization in the United States, Europe, Canada and Israel.

Jan 2017, Ovid and Takeda collaborate to focused on the clinical development and commercialization of Takedas investigational new drug TAK-935, a novel, potent and highly selective CH24H inhibitor, in rare pediatric epilepsies.

In Apr 2015, Lundbeck granted Ovid Therapeutics an exclusive worldwide rights to develop and commercialize gaboxadol (OV101) for the treatment of Angelman Syndrome (AS), a rare neurodevelopmental disorder.

In Aug 2015, Ovid raised $80M in series B financing from Fidelity, Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, DoubleLine Equity Healthcare Fund and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors.